External beam radiation therapy for prostate cancer. 2000

E M Horwitz, and G E Hanks
Department of Radiation Oncology at Fox Chase Cancer Center, Philadelphia, PA, USA.

Men with non-metastatic prostate cancer have many treatment options. For over 35 years, radiation therapy has been a mainstay of treatment for this disease. With improvements in technology and better use of pretreatment prognostic factors, such as prostate specific antigen level and Gleason score, biochemical and clinical results have steadily improved. This article reviews the current status of radiation therapy in the treatment of prostate cancer. Results of treatment utilizing three-dimensional conformal and conventional techniques are compared and contrasted. The appropriate use of adjuvant hormones and particle beam therapy in the management of this disease is also discussed. Finally, the toxicity and future directions of radiation therapy in the treatment of prostate cancer are addressed.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic
D020266 Radiotherapy, Conformal A therapy using IONIZING RADIATION where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators. Conformal Radiotherapy,3-D Conformal Radiotherapy,Three-Dimensional Conformal Radiotherapy,3-D Conformal Radiotherapies,Conformal Radiotherapies,Conformal Radiotherapies, 3-D,Conformal Radiotherapies, Three-Dimensional,Conformal Radiotherapy, 3-D,Conformal Radiotherapy, Three-Dimensional,Radiotherapies, 3-D Conformal,Radiotherapies, Conformal,Radiotherapies, Three-Dimensional Conformal,Radiotherapy, 3-D Conformal,Radiotherapy, Three-Dimensional Conformal,Three Dimensional Conformal Radiotherapy,Three-Dimensional Conformal Radiotherapies

Related Publications

E M Horwitz, and G E Hanks
June 2006, The Journal of urology,
E M Horwitz, and G E Hanks
January 2006, North Carolina medical journal,
E M Horwitz, and G E Hanks
August 1999, International journal of urology : official journal of the Japanese Urological Association,
E M Horwitz, and G E Hanks
June 1984, Journal of the Canadian Association of Radiologists,
E M Horwitz, and G E Hanks
January 2008, Seminars in radiation oncology,
E M Horwitz, and G E Hanks
January 2009, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti,
Copied contents to your clipboard!